# Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD

> **NCT01584505** · PHASE2 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 191 (actual)

## Conditions studied

- Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** CHF1535 + CHF5992 dose 1 BID
- **DRUG:** CHF1535 + CHF5992 dose2 BID
- **DRUG:** CHF1535 daily dose

## Key facts

- **NCT ID:** NCT01584505
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2012-09
- **Final completion:** 2013-01
- **Target enrollment:** 191 (ACTUAL)
- **Last updated:** 2021-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01584505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01584505, "Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01584505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*